Fig. 3 | Scientific Reports

Fig. 3

From: Advanced glycated end-products modified transferrin mediates oxidative stress and ferroptosis in podocytes via advanced glycation end-product receptor in vitro

Fig. 3

The effect of AGE-Tf on oxidative stress in human podocytes. (A), (B), (C), (D), and (E): Comparison of T-AOC, SOD, GSH, LPO, and MDA levels among different groups, respectively. AGE-Tf Advanced glycated end-products modified transferrin, NC Negative control, 0mMGlu-AGE-Tf Glucose concentration is 0 mM when preparing AGE-Tf, 5.6mMGlu-AGE-Tf Glucose concentration is 5.6 mM when preparing AGE-Tf, 11.1mMGlu-AGE-Tf Glucose concentration is 11.1 mM when preparing AGE-Tf, 33.3mMGlu-AGE-Tf Glucose concentration is 33.3 mM when preparing AGE-Tf, DFO deferoxamine mesylate, RAP receptor-for-advanced-glycation-end-productsantagonist peptide, Fer-1 Ferrostatin-1. Data are presented as mean ± SD (n = 3 for all panels) from independent biological replicates;*p < 0.05;**p < 0.01; ***p < 0.001; ****p < 0.0001.

Back to article page